FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Alecensa (alectinib hydrochloride) submitted by Genentech, Inc., resulting in updated labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)